Werewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC Wainwright

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $15.00 price target on the stock.

HOWL has been the subject of several other reports. JMP Securities restated a “market outperform” rating and set a $12.00 target price on shares of Werewolf Therapeutics in a report on Wednesday, June 26th. Wedbush reiterated an “outperform” rating and set a $9.00 price target on shares of Werewolf Therapeutics in a report on Monday, June 3rd.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL opened at $2.14 on Tuesday. The company has a current ratio of 6.71, a quick ratio of 6.71 and a debt-to-equity ratio of 0.24. The firm has a 50-day moving average price of $4.26 and a two-hundred day moving average price of $5.09. Werewolf Therapeutics has a twelve month low of $1.57 and a twelve month high of $8.19. The company has a market capitalization of $92.99 million, a P/E ratio of -1.96 and a beta of 0.47.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Friday, May 3rd. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.15%. The business had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $5.00 million. As a group, research analysts expect that Werewolf Therapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of HOWL. Lighthouse Investment Partners LLC acquired a new stake in shares of Werewolf Therapeutics in the fourth quarter worth approximately $87,000. Certuity LLC acquired a new stake in shares of Werewolf Therapeutics in the fourth quarter worth approximately $39,000. Financial Perspectives Inc boosted its position in shares of Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after acquiring an additional 3,000 shares during the last quarter. Denali Advisors LLC acquired a new stake in shares of Werewolf Therapeutics in the first quarter worth approximately $172,000. Finally, PFM Health Sciences LP boosted its position in shares of Werewolf Therapeutics by 35.6% in the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after acquiring an additional 909,895 shares during the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.